Hansoh Pharma Announces RMB 60 Million Strategic Investment in GlucoCare, Developer of 'Blood Sugar Manager' App

On June 8, Hybio Pharmaceutical announced that it had recently signed a framework agreement with Baishengkang Healthy Technology (Beijing) Co., Ltd. (“Baishengkang”) and its controlling shareholder. Hybio intends to make a strategic investment of RMB 60 million in Baishengkang by subscribing for additional capital, thereby acquiring a 30% equity stake. Baishengkang’s flagship product is the “Hyperglycemia Management” APP.

Glucose Manager focuses on the niche sector of diabetes, developing 45 personalized digital care models categorized by prediabetes, Type 1 diabetes, Type 2 diabetes, pregnancy, and complications, thereby constructing a precision glucose management ecosystem. By leveraging data uploaded by patients, Glucose Manager enables continuous statistical analysis, online physician consultations, and blood glucose risk assessment, while providing timely, personalized health management recommendations covering exercise, diet, and medication.

And the powerful data analytics capabilities of Xuetang Gao are precisely what Hybio values most.

VCBeat Internet Healthcare Research Institute once compiled statistics on the current market status of diabetes apps (clickHere), some are hardware-driven, others are physician-entry-point-driven, while Gaotang Guan believes its approach is driven by the effectiveness or value of diabetes patient management.

Prior to launching its mobile app, Blood Sugar Executive had been dedicated since 2011 to developing server-side health and medical interpretation models, efficacy and operational models for blood glucose management, doctor-patient interaction models, and a physician work platform capable of serving a massive user base. It was not until April 2014 that Blood Sugar Executive began translating its expertise in intelligent blood glucose management into the mobile app. By addressing the diverse needs of individuals with diabetes—varying by type, age, region, medical history, and lifestyle habits—the company developed comprehensive management models covering psychological well-being, medication, exercise, diet, and complication control. This approach enables precise blood glucose management based on users’ health data while respecting their personal preferences.

Precision blood glucose management is achieved through a “many-to-one” model. The term “many” refers to the provision of a dedicated glucose control team for each patient with diabetes, offering professional services. This team typically comprises an internist, a health manager, an exercise specialist, and a nutritionist.

It is reported that Glucose Manager currently hosts 5,000 diabetes specialists and health managers who have established private practices on its platform, with over 200,000 app downloads. Wang Haijun, co-founder of Glucose Manager, has publicly stated that a user-centric mindset was integrated into the product from the outset, which is key to retaining users. “Years of frontline experience in health management have taught us to respect users’ perspectives and needs. We strive to ensure that users are not merely consumers but also creators and participants in our interactive health ecosystem.” The industry-academia-research collaboration between Glucose Manager and the Institute of Electronic Health at Harbin Institute of Technology aims to enhance value-added services for users through dedicated research.

According to Xu Qian, Deputy General Manager of the Investment Department at Fosun Pharma, it is highly challenging to develop distinctive features in chronic disease management. With approximately 100 million diabetes patients in China, every player is eyeing this market, which is currently characterized by homogeneous competition. “In this context, companies are seeking strategic backing, partnering with insurance firms, hospitals, and pharmaceutical companies. However, it remains unclear which type of partnership will ultimately maximize value. Nevertheless, such collaborative models are undoubtedly the prevailing trend.”